Novartis
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Novartis
Jul 9, 2024, 18:09 |
Blog
Daniel Neumeier: Biopharma acquisitions H1/24
Daniel Neumeier, Life Sciences Specialist at L.E.K. Consulting, shared on LinkedIn: "Biopharma acquisitions H1/24 Number…
Jul 1, 2024, 06:22 |
Insight
Partnership with Novartis for over 20 years - The Max Foundation
The Max Foundation shared on LinkedIn: “Thanks to Vas Narasimhan, for recognizing our impactful collaboration.…
Jun 27, 2024, 02:36 |
Opinion
Balraj Sethi: Honored to Speak at the 1st National Cancer Conference!
Balraj Sethi, Country Medical Affairs Head at Novartis, shared a post on LinkedIn: .…
Jun 8, 2024, 23:32 |
Blog
MedEdge MEA - A Memorandum of Understanding with Novartis Middle East and Department of Health Abu Dhabi
MedEdge MEA shared a post on LinkedIn: "At Global Bio Conference 2024, the Department of Health…
May 28, 2024, 01:15 |
Insight
Nirmala Bhoo Pathy: I had the opportunity to facilitate an exciting workshop with Novartis through University of Malaya
Nirmala Bhoo Pathy shared a post on LinkedIn: “Working with pharma? It's true that many…
May 27, 2024, 12:39 |
Societies
Selin Kurnaz: Massive Bio and Precision Cancer Consortium's collaborative abstract accepted at ASCO24
Selin Kurnaz, Co-Founder and CEO at Massive Bio, shared on LinkedIn: "I am beyond proud…
May 23, 2024, 13:48 |
Career
Lori Tomassian: I’m starting a new position as Director, Oncology Transactions, Business Development and Licensing at Novartis!
Lori Tomassian, Director of Oncology Transactions, Business Development and Licensing at Novartis, shared on LinkedIn:…
Apr 30, 2024, 16:14 |
Stories
Pat Garcia-Gonzalez: Ethiopia Revisited - on the strength of the human spirit and progress in the face of adversity
Pat Garcia-Gonzalez, Chief Executive Officer at The Max Foundation, shared on LinkedIn: "Earlier last week,…
Apr 12, 2024, 11:49 |
Drugs
Vasileios Askoxylakis: Promising clinical data from the Phase 1 study of the CCR7 targeting antibody-drug conjugate JBH492
Vasileios Askoxylakis, Vice President, Global Head Oncology Early Clinical Development at Servier, shared on LinkedIn: "Very…
Apr 7, 2024, 07:20 |
Insight
Wafik El-Deiry: Dr. Alice Shaw speaks about directions in ADC’s in cancer therapy at AACR 2024
Wafik El-Deiry, Director of the Legorreta Cancer Center at Brown University, recently posted on LinkedIn:…
Apr 5, 2024, 18:16 |
Insight
Timothée Olivier: NATALEE trial, adjuvant ribociclib 21 days/28 for… 3 years! Cost alert!!
Timothée Olivier, Medical Oncologist at HUG - Geneva University Hospitals, shared a post by the…
Apr 2, 2024, 21:19 |
Career
Lucy Setian: I’m starting a new role as the Director of Patient Experience Strategy and Solutions, Hematology at Novartis!
Lucy Setian, Director of Patient Experience Strategy and Solutions, Hematology at Novartis, made the following…
Mar 21, 2024, 10:46 |
Insight
Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence - UCLA Health
Drug regimen significantly improves invasive disease-free survival for patients with stage 2 or 3 HR-positive,…
Mar 18, 2024, 23:27 |
Blog
Ivana Cattaneo: One week ago five new global teams have been selected to receive up to $25m each over five years to tackle some of cancer's toughest challenges
Ivana Cattaneo, Executive Director Therapeutic Area Advocacy and Precision Medicine at Novartis, shared the following…
Feb 21, 2024, 20:57 |
Blog
Shreeram Aradhye: I have the privilege of hearing directly from patients and what really matters to them when it comes to their treatment
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis made the following post on…
Feb 12, 2024, 16:02 |
Blog
Jean-Paul Kress: MorphoSys announced that it has entered into a business combination agreement to be acquired by Novartis
Jean-Paul Kress, CEO of MorphoSys, shared on LinkedIn: "Last week, MorphoSys announced that it has…
Jan 25, 2024, 14:14 |
Insight
Hung Trinh: Lutathera Cuts Risk of Death by 72% in Neuroendocrine Tumor Treatment
Hung Trinh, Director of Process Development and MFG Science and Technology at Vyriad, posted on…
Jan 12, 2024, 16:58 |
Blog
We are thrilled to announce multi-target research collaborations with Eli Lilly and Company and Novartis - Isomorphic Labs
Sergei Yakneen, Chief Technology Officer at Isomorphic Labs, shared a post by Isomorphic Labs on…
Dec 10, 2023, 17:54 |
Blog
Christian Rutzer: Roche and Novartis - Basel's Research and Innovation Powerhouses
Christian Rutzer, Deputy Head and Lead Scientist at the CIEB University of Basel, shared on…
Nov 14, 2023, 04:01 |
Insight
Pat Garcia-Gonzalez: It is time to re-think advanced breast cancer
Pat Garcia-Gonzalez, Chief Executive Officer at The Max Foundation, shared a post by The Max…
Oct 6, 2023, 16:28 |
Blog
Happy birthday BioRadon! - European Organisation for Research and Treatment of Cancer (EORTC)
Quoting European Organisation for Research and Treatment of Cancer (EORTC) on LinkedIn: “Happy birthday BioRadon!…
Sep 28, 2023, 15:04 |
Dialogues
OncoDaily Dialogues #1 - Harout Semerjian / Hosted by Roupen Odabashian
We're thrilled to launch our new series, "OncoDaily Dialogues". This initiative by OncoDaily is designed…
Aug 19, 2023, 18:44 |
Opinion
Haseeb Ahmad: Comprehensive genomic profiling could help improve treatment and reduce costs for healthcare systems.
According to Haseeb Ahmad, President, Europe at Novartis on LinkedIn: "Up to 40% of cancer…
Jun 22, 2023, 18:35 |
Career
Generic manufacturers sign sublicence agreements with the Medicines Patent Pool to produce generic versions of Novartis’ nilotinib - Medicines Patent Pool
Breaking | 4 generic manufacturers sign sublicence agreements with the Medicines Patent Pool to produce…
Jun 13, 2023, 19:29 |
Insight
So much of the power of science is realized through community - Vas Narasimhan
So much of the power of science is realized through community—through the ways we share…
All:
25
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube